rs141137543
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS1
The NM_002485.5(NBN):āc.1354A>Cā(p.Thr452Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000131 in 1,613,856 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002485.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NBN | NM_002485.5 | c.1354A>C | p.Thr452Pro | missense_variant | 10/16 | ENST00000265433.8 | NP_002476.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NBN | ENST00000265433.8 | c.1354A>C | p.Thr452Pro | missense_variant | 10/16 | 1 | NM_002485.5 | ENSP00000265433.4 |
Frequencies
GnomAD3 genomes AF: 0.000671 AC: 102AN: 152104Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.000223 AC: 56AN: 251218Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135776
GnomAD4 exome AF: 0.0000746 AC: 109AN: 1461634Hom.: 0 Cov.: 32 AF XY: 0.0000550 AC XY: 40AN XY: 727118
GnomAD4 genome AF: 0.000677 AC: 103AN: 152222Hom.: 1 Cov.: 32 AF XY: 0.000725 AC XY: 54AN XY: 74442
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jan 12, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 06, 2020 | In silico analysis supports that this missense variant does not alter protein structure/function This variant is associated with the following publications: (PMID: 30564542, 27443514, 26976419, 25980754, 30309722) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 31, 2022 | BP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 18, 2018 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The NBN p.Thr452Pro variant was identified in 2 of 1738 proband chromosomes (frequency: 0.001) from individuals or families with breast or endometrial cancer (Tung 2016, Ring 2016). The variant was also identified with one other NBN variant and a PALB2 variant, in one individual with primary male breast cancer and primary prostate cancer, though its significance was not conclusive (Kolli 2018). The variant was also identified in dbSNP (ID: rs141137543) as "With other allele", in ClinVar (classified as likely benign by GeneDx and Invitae; uncertain significance by Ambry Genetics, University of Chicago, Mendelics, EGL and ARUP Laboratories), LOVD 3.0 (classified as effect unknown by one submitter). The variant was identified in control databases in 72 of 276950 chromosomes at a frequency of 0.0003 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 61 of 24010 chromosomes (freq: 0.003), Other in 1 of 6456 chromosomes (freq: 0.0002), Latino in 9 of 34394 chromosomes (freq: 0.0003), European Non-Finnish in 1 of 126548 chromosomes (freq: 0.000008); it was not observed in the Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. The p.Thr452 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and 1 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
not specified Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 05, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 07, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 04, 2024 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. | Nov 15, 2022 | - - |
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 11, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 07, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Microcephaly, normal intelligence and immunodeficiency Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
NBN-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 07, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Hereditary cancer Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | Jan 23, 2024 | - - |
Hereditary breast ovarian cancer syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | National Health Laboratory Service, Universitas Academic Hospital and University of the Free State | Apr 19, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at